Regenxbio Inc (RGNX)

$10.31

-0.79

(-7.12%)▲

Live

Performance

  • $10.31
    $11.18
    $10.31
    downward going graph

    0.0%

    Downside

    Day's Volatility :7.78%

    Upside

    7.78%

    downward going graph
  • $9.11
    $28.80
    $10.31
    downward going graph

    11.64%

    Downside

    52 Weeks Volatility :68.37%

    Upside

    64.2%

    downward going graph

Returns

PeriodRegenxbio IncSector (Health Care)Index (Russel 2000)
3 Months
-13.08%
3.6%
0.0%
6 Months
-29.03%
10.2%
0.0%
1 Year
-28.71%
19.6%
0.0%
3 Years
-68.31%
16.8%
-23.0%

Highlights

Market Capitalization
523.9M
Book Value
$7.06
Earnings Per Share (EPS)
-5.24
PEG Ratio
0.26
Wall Street Target Price
38.08
Profit Margin
-270.74%
Operating Margin TTM
-251.34%
Return On Assets TTM
-24.26%
Return On Equity TTM
-63.94%
Revenue TTM
89.0M
Revenue Per Share TTM
1.93
Quarterly Revenue Growth YOY
11.600000000000001%
Gross Profit TTM
-184.3M
EBITDA
-226.0M
Diluted Eps TTM
-5.24
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.64
EPS Estimate Next Year
-1.74
EPS Estimate Current Quarter
-1.29
EPS Estimate Next Quarter
-1.27

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Regenxbio Inc(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
12
Hold
2
2
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 269.35%

Current $10.31
Target $38.08

Company Financials

FY18Y/Y Change
Revenue
218.5M
↑ 2002.42%
Net Income
99.9M
↓ 236.58%
Net Profit Margin
45.74%
↑ 749.76%
FY19Y/Y Change
Revenue
35.2M
↓ 83.88%
Net Income
-94.7M
↓ 194.79%
Net Profit Margin
-268.88%
↓ 314.62%
FY20Y/Y Change
Revenue
154.6M
↑ 338.7%
Net Income
-111.3M
↑ 17.44%
Net Profit Margin
-71.98%
↑ 196.9%
FY21Y/Y Change
Revenue
470.3M
↑ 204.3%
Net Income
127.8M
↓ 214.91%
Net Profit Margin
27.18%
↑ 99.16%
FY22Y/Y Change
Revenue
112.7M
↓ 76.03%
Net Income
-280.3M
↓ 319.27%
Net Profit Margin
-248.68%
↓ 275.86%
FY23Y/Y Change
Revenue
90.2M
↓ 19.94%
Net Income
-263.5M
↓ 6.0%
Net Profit Margin
-291.99%
↓ 43.31%
Q1 FY23Q/Q Change
Revenue
19.1M
↓ 38.94%
Net Income
-70.0M
↑ 16.71%
Net Profit Margin
-365.5%
↓ 174.29%
Q2 FY23Q/Q Change
Revenue
20.0M
↑ 4.38%
Net Income
-72.1M
↑ 3.02%
Net Profit Margin
-360.72%
↑ 4.78%
Q3 FY23Q/Q Change
Revenue
28.9M
↑ 44.74%
Net Income
-61.9M
↓ 14.14%
Net Profit Margin
-213.97%
↑ 146.75%
Q4 FY23Q/Q Change
Revenue
22.2M
↓ 23.18%
Net Income
-62.9M
↑ 1.65%
Net Profit Margin
-283.12%
↓ 69.15%
Q1 FY24Q/Q Change
Revenue
15.6M
↓ 29.67%
Net Income
-63.3M
↑ 0.7%
Net Profit Margin
-405.39%
↓ 122.27%
Q2 FY24Q/Q Change
Revenue
22.3M
↑ 42.72%
Net Income
-53.0M
↓ 16.33%
Net Profit Margin
-237.67%
↑ 167.72%
FY18Y/Y Change
Total Assets
543.8M
↑ 173.72%
Total Liabilities
35.0M
↑ 123.45%
FY19Y/Y Change
Total Assets
497.9M
↓ 8.44%
Total Liabilities
47.7M
↑ 36.45%
FY20Y/Y Change
Total Assets
708.2M
↑ 42.23%
Total Liabilities
330.4M
↑ 592.53%
FY21Y/Y Change
Total Assets
1.1B
↑ 57.29%
Total Liabilities
349.6M
↑ 5.81%
FY22Y/Y Change
Total Assets
833.3M
↓ 25.19%
Total Liabilities
317.1M
↓ 9.31%
FY23Y/Y Change
Total Assets
574.0M
↓ 31.12%
Total Liabilities
262.2M
↓ 17.3%
Q1 FY23Q/Q Change
Total Assets
747.8M
↓ 10.25%
Total Liabilities
282.7M
↓ 10.84%
Q2 FY23Q/Q Change
Total Assets
682.5M
↓ 8.74%
Total Liabilities
276.6M
↓ 2.15%
Q3 FY23Q/Q Change
Total Assets
633.8M
↓ 7.13%
Total Liabilities
270.7M
↓ 2.14%
Q4 FY23Q/Q Change
Total Assets
574.0M
↓ 9.44%
Total Liabilities
262.2M
↓ 3.12%
Q1 FY24Q/Q Change
Total Assets
629.2M
↑ 9.63%
Total Liabilities
238.5M
↓ 9.03%
Q2 FY24Q/Q Change
Total Assets
569.4M
↓ 9.51%
Total Liabilities
221.1M
↓ 7.31%
FY18Y/Y Change
Operating Cash Flow
104.6M
↓ 280.45%
Investing Cash Flow
-279.4M
↑ 5732.11%
Financing Cash Flow
204.4M
↑ 141.66%
FY19Y/Y Change
Operating Cash Flow
-107.7M
↓ 202.92%
Investing Cash Flow
93.6M
↓ 133.49%
Financing Cash Flow
8.4M
↓ 95.9%
FY20Y/Y Change
Operating Cash Flow
-54.1M
↓ 49.81%
Investing Cash Flow
122.8M
↑ 31.21%
Financing Cash Flow
200.2M
↑ 2290.33%
FY21Y/Y Change
Operating Cash Flow
218.9M
↓ 504.87%
Investing Cash Flow
-406.6M
↓ 431.25%
Financing Cash Flow
195.3M
↓ 2.48%
FY22Y/Y Change
Operating Cash Flow
-207.5M
↓ 194.8%
Investing Cash Flow
-11.9M
↓ 97.07%
Financing Cash Flow
-28.8M
↓ 114.77%
Q1 FY23Q/Q Change
Operating Cash Flow
-80.9M
↑ 105.52%
Investing Cash Flow
63.1M
↑ 136.31%
Financing Cash Flow
-9.0M
↑ 1.31%

Technicals Summary

Sell

Neutral

Buy

Regenxbio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Regenxbio Inc
Regenxbio Inc
-4.88%
-29.03%
-28.71%
-68.31%
-71.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Regenxbio Inc
Regenxbio Inc
12.06
NA
0.26
-4.64
-0.64
-0.24
NA
7.06
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Regenxbio Inc
Regenxbio Inc
Buy
$523.9M
-71.77%
12.06
-270.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Regenxbio Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 15.62M → 22.29M (in $), with an average increase of 29.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -63.33M → -52.98M (in $), with an average increase of 19.5% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 114.2%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 113.1%

Institutional Holdings

  • BlackRock Inc

    17.42%

  • Vanguard Group Inc

    10.35%

  • Redmile Group, LLC

    9.25%

  • JPMorgan Chase & Co

    6.10%

  • State Street Corp

    5.81%

  • Avidity Partners Management LP

    2.63%

Company Information

regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.

Organization
Regenxbio Inc
Employees
344
CEO
Mr. Curran M. Simpson M.S.
Industry
Health Technology

Discover More

FAQs